COST-EFFECTIVENESS OF RECOMBINANT HUMAN FOLLICLE STIMULATING HORMONE BIOSIMILARS IN PORTUGAL
Author(s)
Silverio N, Botica F, Batista AR
Merck SA, Lisboa, Portugal
Presentation Documents
OBJECTIVES: To estimate the cost-effectiveness of the original r-hFSH (Gonal-f) when compared with one biosimilar (Ovaleap) using the evidence from a head-to-head registration trial. METHODS:
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PIH18
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Reproductive and Sexual Health
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now